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We Have Journeyed Far*
Ileana L. Pin˜a, MD
Philadelphia, Pennsylvania
It is well to acknowledge the debt which we every-day
practitioners owe to the great leaders and workers in the
scientific branches of our art. We dwell too much in corners,
and, consumed with the petty cares of a bread-and-butter
struggle, forget that outside our routine lie Elysian fields
into which we may never have wandered. . . .
Sir William Osler, 1891
The article by Goldberg and colleagues found in this issue is
a meticulous history of the changes in incidence and
in-hospital and long term case fatality rates of myocardial
infarction (MI) for a defined New England community
from 1975 to 1995 (1). The authors suggest that there is a
decline in the incidence of acute MI as well as in the short
term and one-year mortality in survivors postdischarge. In
the current era of thrombolysis, polypharmacy and ever-
shorter hospital stays with tighter allocation of resources, it
is easy to forget how far we have come in the treatment of
MI. It is equally easy, however, to envision where we should
be in the new millennium. Nonetheless, Goldberg et al.
invite us to recall the advances made in the treatment of the
acute MI from 1975 to the present and to encourage
reflection on future directions (1).
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Mortality. In 1962, when coronary care units were devel-
oped, the short-term mortality for MI was 30% to 40%,
with 40% due to arrhythmic deaths (2–4). The groundwork
for coronary units had already begun when in 1960 Zoll
published a description of externally applied countershock
to terminate lethal ventricular arrhythmias and Kowen-
houven introduced closed cardiac massage, which was the
beginning of modern cardiopulmonary resuscitation (5,6).
The ability to treat acute arrhythmias facilitated the devel-
opment of sophisticated monitoring equipment and allowed
the proliferation of coronary care units both in the U.S. and
abroad (2,3). In Day’s initial coronary care unit, the mor-
tality of the first 62 patients had already decreased to 19%.
Many, however, continued to succumb to ventricular ar-
rhythmias, even in coronary units. Subsequently, in 1967,
Lown and associates reported that the use of prophylactic
intravenous lidocaine decreased the occurrence of primary
ventricular fibrillation (4). Thus, the era of prevention of
ventricular fibrillation began. From 1967 to 1971, the
mortality rates for MI treated in coronary units ranged from
12% to 25%, particularly in patients without severe conges-
tive heart failure (7,8). Coronary units had become primarily
areas to monitor arrhythmias closely and treat them
promptly.
In 1967, the use of coronary care units became expanded
to include the “rule-out myocardial infarction” patients after
Lown and colleagues stated that if admission were delayed
until a diagnosis was firmly made, then “a significant
number of patients will succumb to preventable electrical
death” (9). As the selection of patients to coronary care units
became less stringent, and the dynamic evolution of infarc-
tion became known, specialists began to study interventions
to limit infarct size. In the late 1970s, the medical commu-
nity started to recognize that the size of the infarct was
directly related to the development of congestive heart
failure or cardiogenic shock. Methods proposed to limit
infarct size included beta-adrenergic blockers, nitroglycerin,
surgical revascularization and the use of balloon counterpul-
sation, among others (10–13).
This brief chronicle now brings us to the early decade
described by Goldberg et al. (1). The crude in-hospital case
fatality rate in 1975 to 1978 was somewhat better than that
described in 1970 (24% vs. 17.8%) when compared to the
Minnesota Heart Survey and comparable to the 1985 figures
(14% vs. 14.9%) for the period of 1981 to 1984 (14). Both
the Minnesota Heart Survey and the current report by
Goldberg are population-based studies, all-inclusive, and do
not select out the more complex patients as is often the case
in clinical trials (1,14). Thus, there is merit in assessing and
reviewing the influence of therapies on the general popula-
tion.
The earlier years (1975 to 1978 and 1981 to 1984) could
truly be called the prethrombolytic period. It is interesting
to remember that in 1981, the cardiology community was
still debating whether coronary thrombosis was primary or
secondary in acute infarction, although by then, DeWood et
al. had demonstrated that in 90% of infarct-related arteries
there was complete occlusion and Rentrop had reported
reperfusion of the infarct related artery in over 75% of
patients within the first 3 h of chest pain (15–17). These
facts are even more amazing when one considers that
visionaries such as Sherry and Fletcher had in 1958 and
1959 described the use of streptokinase in a small group of
patients with acute MI with an encouraging lower mortality
in the absence of major systemic toxicity (18,19). Subse-
quent major trials showed reduction in mortality using
reperfusion early in the evolution of MI (20). For the first
time, physicians became convinced that infarct size could be
limited, and thus, the era of thrombolysis had begun.
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Although the in-hospital mortality data of Goldberg and
associates is not as low as is reported in controlled clinical
trials, the definite decline in the fatality rate is worthy of
note. As duly observed by the authors, population studies do
not control for differences in treatment strategies. Much of
the decline in mortality can be attributed to the use of
thrombolytic agents in addition to other therapies such as
ACE inhibitors, beta-adrenergic blocking agents and anti-
platelet agents.
Now that mortality rates as low as 4% have been reported,
where do we progress from this point (21)? In the ideal
world, there should be no “treatment gap.” For example,
therapies proved to be life-saving should be applied to all
eligible patients. The “treatment gap”, however, does exist.
In 1996, the joint Committee on the Management of Acute
Myocardial Infarction of the American Heart Association
and the American College of Cardiology recommended that
thrombolytic therapy be administered to all patients regard-
less of age, gender or race who have symptoms suggestive of
an acute MI and who present within 12 h of onset of
symptoms (22). Furthermore, in patients with an increased
risk of bleeding, primary angioplasty or bypass surgery
should be considered. In spite of these recommendations,
the elderly and women are less likely to receive thrombolytic
therapy in addition to patients with a past history of heart
failure or who have a bundle-branch block on initial ECG.
In fact, up to 24% of patients who are eligible for this
therapy do not receive it (23–25). In the population of
inclusive infarctions in Worcester, the percent of patients
receiving thrombolytics was only 29% to 30%, and did not
significantly change from 1990 to 1995 (1). Efforts must
continue to close the gap between the randomized trials and
clinical practice. The reduction in cardiovascular mortality
needs to be extended to women, the elderly and those at
highest risk for in-hospital mortality. This should be one of
the directions toward mortality reduction in the next mil-
lennium. Furthermore, as underscored by the findings of
Goldberg et al., the use of angiotensin converting enzyme
inhibitors increased from 1990 to 1995 (1). However, data
from the National Registry of Myocardial Infarction have
observed that most high-risk patients are not receiving
ACE inhibitors, because only 26% of patients with an
anterior wall MI were discharged on this treatment (26).
The numbers are nearly identical to those of Goldberg et al.
(1).
Incidence. The life-saving interventions discussed here
would not be necessary if the incidence of MI were
significantly reduced. The reported decreases in the inci-
dence of MI in Worcester, Massachusetts are indeed en-
couraging and mirror other reports of population studies
(1,27). Nadir of the decline occurred in the late 1980s with
subsequent increases in incidence in 1991, 1993, and 1995
that were not as high as in the earlier decade. Although one
would hope that greater awareness of blood pressure level,
cholesterol measurements and the risks of smoking are
responsible for the decline, other risks, such as obesity and
inactivity continue to rise in the U.S. It is most interesting
to note that the percent of patients with an antecedent
history of hypertension and diabetes rose from 1975 to
1995. Thus, the presence of two highly significant risk
factors has not diminished. The observations of these
investigators emphasize the need for continued primary
prevention and national efforts to curb smoking, a focus on
obesity and the physician’s role in blood pressure and lipid
control. Programs at the local community level should be
developed to encourage physical activity.
Finally as encouraging as these data may seem, the rate of
hospitalizations for heart failure have been increasing during
the same two decades, particularly in the elderly (28).
Because coronary artery disease is the most common cause
of heart failure in the U.S., one hopes that the clinical
application of the treatment trials, i.e., use of thrombolytics,
antiplatelet agents, beta-adrenergic blockers and ACE in-
hibitors in conjunction with aggressive primary and second-
ary prevention programs will eventually decrease the inci-
dence of heart failure as well (29). In summary, the
“treatment gap” needs closure.
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